Literature DB >> 15556142

Effects on rat thalamic proteome by acute and subchronic MK-801-treatment.

Linda Paulson1, Peter Martin, Elisabeth Ljung, Kaj Blennow, Pia Davidsson.   

Abstract

Since the symptoms of intoxication with non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists closely mimic symptoms in patients with schizophrenia, [+]-5-methyl-10,11-dihydro-5H-dibenzo-[a,d]-cycloheptene-5,10-iminehydrogenmaleate (MK-801)-treated rodents are often used as a model for schizophrenia. In most studies, acute injections of MK-801 to rats have been used, but in some studies, longer periods of treatment have been performed. In our previous work, alterations in mRNA/protein expression were screened in the cerebral cortex of MK-801 treated rats. Different proteins were altered in different treatment courses of MK-801. The main objective of the present study was to evaluate different treatment periods of treatment with MK-801 in rats as a model for schizophrenia. Thalamus proteins from treated (acute, six and 12 days) and control rats were analyzed with two-dimensional gel electrophoresis and mass spectrometry. Our results show that different treatment times of MK-801 to rats give different biochemical results. Therefore, it is important to use the same treatment time in studies that will be compared.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15556142     DOI: 10.1016/j.ejphar.2004.10.036

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  NMDA receptor hypofunction induces dysfunctions of energy metabolism and semaphorin signaling in rats: a synaptic proteome study.

Authors:  Kejun Zhou; Yifeng Yang; Linghan Gao; Guang He; Weidong Li; Kefu Tang; Baohu Ji; Ming Zhang; Yang Li; Jinglei Yang; Liya Sun; Zhao Zhang; Hui Zhu; Lin He; Chunling Wan
Journal:  Schizophr Bull       Date:  2010-11-17       Impact factor: 9.306

2.  Proteome analysis after co-administration of clozapine or haloperidol to MK-801-treated rats.

Authors:  L Paulson; P Martin; E Ljung; K Blennow; P Davidsson
Journal:  J Neural Transm (Vienna)       Date:  2007-02-22       Impact factor: 3.850

3.  In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug.

Authors:  Yanan Xu; Xiaoyin Zhu; Hongbo Wang; Shanyue Sun; Xin Yue; Jingwei Tian
Journal:  Sci Rep       Date:  2018-05-02       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.